UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
__________________________
 
FORM 8-K
 
__________________________
 
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported) December 15, 2004
 
__________________________
 
NOVADEL PHARMA INC.
(Exact Name of Registrant as Specified in Its Charter)
 
__________________________
 
         
Delaware
 
001-32177
 
22-2407152
(State or other jurisdiction
of incorporation)
 
 
(Commission File No.)
 
(I.R.S. Employer
Identification No.)
 
 
25 Minneakoning Road
Flemington, New Jersey 08822
(Address of principal executive offices) (Zip Code)
 
(908) 782-3431
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)
 
__________________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


  
     
 

Item 2.02. Results of Operations and Financial Condition.
 
On December 15, 2004, the Registrant issued a press release to report its financial results for the quarter ended October 31, 2004. A copy of the press release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.
 
Item 9.01. Financial Statements and Exhibits.
 
(c) Exhibits.
   99.1      Press Release dated December 15, 2004
 
This press release is being furnished pursuant to Item 9.01 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

 
     
 


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  
     
  NovaDel Pharma Inc.
 
 		  
 		  
 
Date: December 17, 2004 By:   /s/  Jean W. Frydman
 
Name: Jean W. Frydman
  Title: Vice President and General Counsel